PIK3CA mutations occur in ~30-50% of endometrioid endometrial cancers, often co-occurring...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-PIK3CA-HOTSPOT-ENDOMETRIAL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-ENDOMETRIAL |
| Sources | SRC-CIVIC SRC-ESGO-ENDOMETRIAL-2025 SRC-NCCN-UTERINE-2025 |
Actionability Facts
| Biomarker | BIO-PIK3CA-MUTATION |
|---|---|
| Variant | hotspot (E545K / E542K / H1047R) |
| Disease | DIS-ENDOMETRIAL |
| ESCAT tier | IIIA |
| Recommended combinations | everolimus + letrozole, capivasertib (off-label tissue-agnostic rationale) |
| Evidence summary | PIK3CA mutations occur in ~30-50% of endometrioid endometrial cancers, often co-occurring with PTEN loss. PI3Ki/AKTi/mTORi monotherapy modest activity (everolimus + letrozole recommended). Tissue-agnostic capivasertib not formally approved in endometrial. |
Notes
ESCAT IIIA. POLE/MMR/p53 molecular subtype guides primary 1L choice (dostarlimab/pembrolizumab + carbo/pacli).
Used By
No reverse references found in the YAML corpus.